The European Commission approved Novo Holdings’ $16.5 billion acquisition of Catalent, a contract drug manufacturer, removing obstacles to the deal. The acquisition, which has sparked debate over competition in the pharmaceutical industry, is still pending approval from the U.S. Federal Trade Commission. Novo Holdings, the parent company of Novo Nordisk, aims to buy Catalent due to its role in manufacturing the weight loss drug Wegovy. However, concerns have been raised about Novo Holdings selling three Catalent facilities to Novo Nordisk for $11 billion as part of the deal. The deal has generated significant industry interest and scrutiny.
Source link
European regulators approve $16.5B deal for Novo Holdings to buy Catalent
